Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

WATERTOWN, Mass., May 11 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.  The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer's disease patients.

"Patients with Alzheimer's disease have a number of symptomatic therapies available to them. However, the effects of the available medications are modest. Even if significant progress is made in slowing disease progression, more effective therapies that sustainably improve the cognition of the patients are clearly needed," said Kees Been, EnVivo president and CEO. "There is growing consensus that alpha-7 nicotinic agonists can potentially improve the cognitive function in Alzheimer's disease patients as evidenced by the number of large pharmaceutical companies advancing similar drugs through development. The potential upside for patients is considerable and we look forward to completing our Alzheimer's disease study by the middle of next year."

The Phase IIb study will enroll mild to moderate Alzheimer's disease patients who will be randomized to three separate doses of EVP-6124 or placebo over six months. Efficacy will primarily be determined by the ADAS-Cog scale, a commonly used and accepted measure of cognition in patients with Alzheimer's disease. Secondary assessments will include other cognitive and clinical measures. EVP-6124 also is being tested in patients with schizophrenia in a separate Phase IIb study that started in late 2009
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Culver City, CA (PRWEB) May 20, 2013 ... Trustees has announced the appointment of Lisa Baird as ... WMIS on July 8, 2013. The WMIS ... multi-modal imaging applications to understand and effectively treat diseases ... Molecular Imaging Society (WMIS) was established in 2011 by ...
(Date:5/17/2013)... Dr. Sparano is Professor of Medicine ... the Albert Einstein College of Medicine and Associate Chairman ... Center. He is also Associate Director for Clinical ... Einstein Breast Cancer Working Group, a multidisciplinary group of ... He also serves as Vice Chair of the National ...
(Date:5/17/2013)... Elsevier, a world-leading provider of scientific, technical and medical ... a recent study in Reproductive BioMedicine Online ... those with an abnormal chromosomal composition can be identified ... blastocysts, thereby classifying the risk of genetic abnormality without ... has undertaken a retrospective study, using their predictive model ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
Breaking Biology Technology:WMIS Appoints Lisa Baird as Next Executive Director 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... Technology Development for the Conversion of Biomass to ... Netherlands, November 1, Khosla Ventures and BIOeCON announce ... Khosla Ventures, will provide the Series A,funding, whereas ... the ,Biomass Catalytic Cracking Process, (BCC). KiOR Inc. ...
... 1 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President,and CEO of ... a,corporate overview of the Company at the Acumen BioFin ... 6, 2007 at 3:20 p.m. ET.,The event will be ... 5-7,2007. A live audio webcast of the presentation ...
... the Most Advanced ... Bio-Science Imaging Protocols, MELVILLE, N.Y., Nov. ... launch of its latest,inverted microscope series, the Eclipse Ti. Available ... flexibility and efficient,multi-mode microscopy as part of a fully-integrated microscope ...
Cached Biology Technology:Khosla Ventures and BIOeCON Form KiOR Inc. 2Khosla Ventures and BIOeCON Form KiOR Inc. 3Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Nikon Unveils the Eclipse Ti Inverted Microscope Series at The Society for Neroscience Annual Meeting 2Nikon Unveils the Eclipse Ti Inverted Microscope Series at The Society for Neroscience Annual Meeting 3
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... The iCargo project (Intelligent Cargo in Efficient and Sustainable ... thanks to an improvement in the efficiency of intermodal ... assist decision making. It comprises 29 European organisations with ... management. It has a budget totalling 17,000,000 and a ... is working to specify and develop the semantic components ...
(Date:5/17/2013)... An international team of scientists ... and cell movement inside a living frog embryo in ... new method to advance biological research and the search ... University and the Karlsruher Institut fr Technologie in Germany, ... U.S. Department of Energy,s Argonne National Laboratory, released the ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2New X-ray method shows how frog embryos could help thwart disease 2
... Service (MMS) and National Oceanographic and Atmospheric Administration (NOAA) ... about the prey of sperm whales in the northern ... three legs was completed on February 10, 2010 and ... legs of the cruise departed from the NOAA Fisheries ...
... last year as a possible "missing link" between humans and ... lorises, according to two papers by scientists at The University ... Chicago. In an article now available online in the ... that the 47-million-year-old Darwinius masillae is not a ...
... Following an intense study of agricultural ecosystems ... simultaneous analysis and management of a wide range ... Raudsepp-Hearne of McGill University,s Department of Geography, Elena ... Garry Peterson of the Stockholm Resilience Centre at ...
Cached Biology News:MMS and NOAA scientists study prey of Gulf of Mexico sperm whales 2Recently analyzed fossil was not human ancestor as claimed, anthropologists say 2Recently analyzed fossil was not human ancestor as claimed, anthropologists say 3Seeing the hidden services of nature 2
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Biology Products: